Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021207420 - AN INNOVATIVE DNA VACCINE FOR SARS-COV, SARS-COV-2, AND MERS-COV

Publication Number WO/2021/207420
Publication Date 14.10.2021
International Application No. PCT/US2021/026268
International Filing Date 07.04.2021
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61K 38/38 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
38Albumins
A61K 48/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/165 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
C12N 7/01 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
CPC
A61K 2039/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
53DNA (RNA) vaccination
A61K 38/38
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
38Albumins
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Applicants
  • THE JOHNS HOPKINS UNIVERSITY [US]/[US]
Inventors
  • WU, T.C.
  • HUNG, Chien-Fu
  • TSAI, Ya Chea
  • TSENG, Ssu-Hsueh
  • RODEN, Richard, B.S.
Agents
  • SAPPENFIELD, Christopher, C.
Priority Data
63/007,60809.04.2020US
63/042,26022.06.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) AN INNOVATIVE DNA VACCINE FOR SARS-COV, SARS-COV-2, AND MERS-COV
(FR) VACCIN À ADN INNOVANT CONTRE LES SARS-COV, SARS-COV-2 ET MERS-COV
Abstract
(EN) Provided herein are DNA vaccine constructs comprising linking polynucleotides encoding human albumin to polynucleotides comprising one or more of the receptor binding domains (RBD) of the spike protein of SARS-CoV-2 and/or MERS-CoV and/or SARS-CoV. Methods for making the vaccine constructs and their use in prophylaxis and treatment of SARS coronavirus infections are also provided.
(FR) L'invention concerne des constructions de vaccin à ADN comprenant la liaison de polynucléotides codant pour l'albumine humaine à des polynucléotides comprenant un ou plusieurs des domaines de liaison au récepteur (RBD) de la protéine de spicule du SARS-CoV-2 et/ou du MERS-CoV et/ou du SARS-CoV. L'invention concerne également des procédés de préparation des constructions de vaccin et leur utilisation dans la prophylaxie et le traitement d'infections par un coronavirus responsable du SRAS.
Latest bibliographic data on file with the International Bureau